An acneiform-like skin toxicity is commonly observed in patients with solid tumors treated with epidermal growth factor receptor inhibitors (EGFRIs). This symptomatic rash is related to epidermal growth factor receptor (EGFR) inhibition in the skin. A positive relation between the presence and severity of treatment-related rash and survival has been consistently observed with all EGFRIs approved for clinical use. These findings suggest that rash may be a useful surrogate marker of successful EGFR inhibition and clinical benefit and therefore of possible use in identifying patients most likely to benefit from therapy, as well as to guide dose adjustments. Increasing drug dose until skin toxicity appears is being studied. Further studies are needed to thoroughly evaluate the value of skin toxicity as a surrogate marker for clinical benefit. Current treatments of the skin toxicity are empirical and oriented toward mitigating symptoms and not validated by well-controlled clinical trials. Rational treatments based on the biological mechanisms of the skin toxicity must be developed and tested in well-controlled clinical trials.
The involvement of epidermal growth factor receptor (EGFR)–mediated signaling pathways in a variety of human solid tumors makes targeted inhibition of EGFR a rational approach to anticancer therapy. Results from preclinical and clinical studies suggest that EGFR inhibitors (EGFRIs) have inherent antitumor activity against a range of malignancies, as well as the ability to enhance the effects of conventional chemotherapy and radiotherapy.[1,2]
An acneiform-like skin rash is a common toxicity observed with both EGFR-targeted monoclonal antibodies and tyrosine kinase inhibitors (TKIs). The rash, which is most commonly seen above the waist and particularly around the nose, is characterized by clusters of monomorphic pustular lesions. The condition appears to be dose related, symptomatic to the point of requiring intervention in about one-third of patients, and self-limiting, usually resolving on discontinuation of therapy. The rash is thought to be directly related to inhibition of EGFR in the skin, leading to follicular occlusion as a consequence of the lack of differentiation in the epithelium, and release of cytokines that lead to epithelial inflammation.
The EGFR is expressed ubiquitously in epithelial and stromal cells, as well as in select glial and smooth-muscle cells. In normal skin, the EGFR is constitutively expressed in the epidermis, sebaceous glands, and hair follicle epithelium.[4,5] Under physiologic conditions, EGFR activity is tightly regulated and mediates normal cellular growth and proliferation, such as the differentiation of skin follicles and keratinocytes. Murine studies indicate that complete or partial abrogation of the EGFR gene causes significantly altered and thinned epidermis and abnormal colonic mucosa, which suggests that the downstream signaling cascade for EGFR is essential for normal development of epithelial tissues.[7,8]
The acneiform-like skin toxicity characteristic of EGFR inhibition likely reflects the positive EGFR status of epidermal keratinocytes and other skin cells and supports the hypothesis that the antitumor effects of EGFRIs are caused by inhibition of EGFR signaling. A consistently high incidence of rash, which generally takes the form of erythematous follicular papules and pustules, has been observed in patients treated with EGFR-specific monoclonal antibodies (eg, cetuximab [Erbitux], panitumumab [Vectibix], or matuzumab) and with small-molecule EGFR TKIs (eg, gefitinib [Iressa] and erlotinib [Tarceva], see Table 1).
Some anti-EGFR monoclonal antibodies, such as RG83852, do not inhibit the tyrosine kinase activity of the receptor, but are actually partially agonistic. In a phase I study of RG83852, no skin rash was observed at doses that produced a high level of saturation of EGFR in vivo. This observation provides further support of the notion that the skin rash requires effective EGFR tyrosine kinase (TK) inhibition; however, TK inhibition may be necessary, but not sufficient, for the skin rash to occur.
A certain susceptibility to development of skin rash may be important because the degree of toxicity varies from patient to patient, and a significant number of patients do not develop rash at doses that result in significant EGFR TK inhibition. Studies to determine and characterize the possible immunologic basis of this individual susceptibility are needed to more fully understand the pathophysiology of the rash and to interpret the clinical observations that suggest a link between the occurrence of rash and improved survival. Rash may be an indicator of the degree of EGFR function inhibition and may predict objective tumor response or clinical benefit in cancer patients. The presence and severity of the rash could, therefore, serve as a useful guide for early selection of patients to continue treatment or for titrating EGFRI dosing to achieve an optimal response.
Roman Perez-Soler has served as a consultant for Genentech, OSI Pharmaceuticals, Amgen, ImClone, and GlaxoSmithKline; has stock in Genentech, OSI Pharmaceuticals, Amgen, Novartis, and AstraZeneca; has received honoraria from Genentech, Amgen, OSI Pharmaceuticals, ImClone, AstraZeneca; and has received research funds from OSI Pharmaceuticals; Eric Van Cutsem has served as a consultant and received research funds from Roche.
Funding for this supplement was provided by Amgen.
1. Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459, 2005.
2. Khalil MY, Grandis JR, Shin DM: Targeting epidermal growth factor receptor: Novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 3:367-380, 2003.
3. Wells A: EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999.
4. Green MR, Couchman JR: Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle. J Invest Dermatol 83:118-123, 1984.
5. Busam KJ, Tan LK, Granter SR, et al: Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. Mod Pathol 12:786-793, 1999.
6. Jost M, Kari C, Rodeck U: The EGF receptor—An essential regulator of multiple epidermal functions. Eur J Dermatol 10:505-510, 2000.
7. Threadgill DW, Dlugosz AA, Hansen LA, et al: Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269:230-234, 1995.
8. Sibilia M, Wagner EF: Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269:234-238, 1995.
9. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non–small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002.
10. Perez-Soler R, Donato NJ, Shin DM, et al: Tumor epidermal growth factor receptor studies in patients with non–small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 12:730-739, 1994.
11. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non–small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005.
12. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001.
13. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004.
14. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 22:3238-3247,2004.
15. Bonner JA, Giralt J, Harari PM, et al: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab (abstract 5507). Proc Am Soc Clin Oncol 23:2004.
16. Cohen RB, Falcey JW, Paulter VJ, et al: Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr positive tumors (abstract 1862). Proc Am Soc Clin Oncol 19:474a, 2000.
17. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004.
18. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004.
19. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 22:2610-2616, 2004.
20. Busam KJ, Capodieci P, Motzer R, et al: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169-1176, 2001.
21. Boucher KW, Davidson K, Mirakhur B, et al: Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 47:632-633, 2002.
22. Monti M, Mancini LL, Ferrari B, et al: Complications of therapy and a diagnostic dilemma case. Case 2: Cutaneous toxicity induced by cetuximab. J Clin Oncol 21:4651-4653, 2003.
23. Rowinsky EK, Schwartz GH, Gollob JA, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015, 2004.
24. Clark GM, Perez-Soler R, Siu L, et al: Rash severity is predictive of increased survival with erlotinib HCI (abstract 786). Proc Am Soc Clin Oncol 22:196, 2003.
25. Malik SN, Siu LL, Rowinsky EK, et al: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9:2478-2486, 2003.
26. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005.
27. Hirsch F, McCoy J, Cappuzzo F, et al: FISH and immunohistochemistry (IHC) can be used to select NSCLC patients who will not benefit from gefitinib treatment (abstract O-107). Lung Cancer 49:S38, 2005.
28. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer—Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005.
29. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005.
30. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004.
31a. Bailey LR, Kris M, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non–small-cell lung cancer: IDEAL 1 and 2 (abstract LB-170). Proc Am Assoc Cancer Res 44:1362, 2003.
31b. Berlin J, Neubauer M, Swanson P, et al: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr). J Clin Oncol 24(suppl 18):3548 (abstract 3548), 2006.
31c. Hecht JR, Mitchell E, Baranda J, et al: Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. J Clin Oncol 24(suppl 18)3547a (abstract 3547), 2007.
32. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909, 2005.
33. Niho S, Kubota K, Goto K, et al: First-line single agent of gefitinib in patients (pts) with advanced non–small cell lung cancer (NSCLC): A phase II study (abstract 7059). Proc Am Soc Clin Oncol 23:628, 2004 (slide presentation available at www.asco.org).
34a. Bell DW, Lynch TJ, Haserlat SM, et al: Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092, 2005.
34b. Juan T, Freeman D, Sarosi I, et al: Association of Somatic KRAS Gene Mutations and Clinical Outcome from a Phase 2 mCRC Trial of Panitumumab. Presented at the 9th World Congress of Gastrointestinal Cancer, June 20-27, 2007, Barcelona, Spain. Abstract 594.
34c. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer: Results from a randomized, controlled trial. Presented at the 14th Biannual European Cancer Conference (ECCO); Sep 23-27, 2007, Barcolona, Spain. Abstract 0007.
35. Saltz L, Kies M, Abbruzzese JL, et al: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies (abstract 817). Proc Am Soc Clin Oncol 22:204, 2003.
36. Herbst RS, Prager D, Hermann R, et al: TRIBUTE—A phase III trial of erlotinib HC1 (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non–small cell lung cancer (NSCLC) (abstract 7011). Proc Am Soc Clin Oncol 23:617, 2004 (slide presentation available online at www.asco.org).
37. Shepherd FA, Pereira J, Ciuleanu TE, et al: A randomized placebo-controlled trial of erlotinib in patients with advanced non–small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial (abstract 7022). Proc Am Soc Clin Oncol 23:2004 (slide presentation available online at: www.asco.org).
38. Van Cutsem E, Peeters M, Gelderblom H, et al: Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST) (abstract O-0034). Presented at the World Congress on Gastrointestinal Cancer, Barcelona, 2007.
39. Tejpar S, Peeters M, Humblet H, et al: Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data (abstract 4037). J Clin Oncol 25(suppl 18S):172s, 2007 (slide presentation available at www.asco.org).
40. Perez-Soler R, Zou Y, Li T, et al: Topical vitamin K3 (Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin (abstract 3036). J Clin Oncol 24(suppl 18S):129s, 2006 (slide presentation available at www.asco.org).
41. Perez-Soler R, Zou Y, Li T, et al: Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of the skin rash (abstract 9124). J Clin Oncol 25(suppl 18S):523s, 2007 (slide presentation available at www.asco.org).
42. Lenz HJ, Van Cutsem E, Khambata-Ford S: Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol 24: 4914-4921, 2006.
43. Rosell R, Daniel C, Ramlau R, et al: Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non–small-cell lung cancer (NSCLC) (abstract 7012). Proc Am Soc Clin Oncol 23:618, 2004 (slide presentation available at www.asco.org).
44. Hecht JR, Patnaik A, Berlin J, et al: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110(5):980-988, 2007.
45a. Crawford J, Sandler AB, Hammond LA, et al: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) (abstract 7083). Proc Am Soc Clin Oncol 23:634, 2004.
45b. VanCutsem E, Siena S, Humblet Y, et al: An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology, in press.
46. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007.
47. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003.
48. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial. JAMA 290:2149-2158, 2003.
49. Cohen EEW, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003.
50. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: A phase III trial—INTACT 1. J Clin Oncol 22:777-784, 2004.
51. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: A phase III trial—INTACT 2. J Clin Oncol 22:785-794, 2004.
52. Gatzemeier U, Pluzanska A, Szczesna A, et al: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) (abstract 7010). Proc Am Soc Clin Oncol 23:617, 2004.
53. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433, 2005.
54. Van Cutsem E: Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. The Oncologist 11:1010-1017, 2006.
55. Perez-Soler R: Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 8 (suppl 1):S7-S14, 2006.
56. Wacker B, Nagrani T, Weinberg J, et al: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921, 2007.